Tuesday, 12 June 2012

Alex Ruus on BNN: “This (Neptune) could be a 10 bagger type stock”

Neptune Technologies & Bioressources
Basic Shares: 48.2 million
Fully diluted: 53.9 million

Yesterday on the BNN show MarketSense, Alex Ruus, VP & Portfolio Manager at BluMont Capital named Neptune Technologies a Top Pick. At approximately 4 minutes 10 seconds into the spot, he mentions the Acasti Pharma (Neptune subsidiary) Phase Two clinical trials, which he says are going very well.

“We expect some big news coming out of the company later on this year, which will catapult this stock to all time highs.” Of note: Neptune’s all time high was just over $8 back in 2007.

To view Mr. Ruus on BNN, please click here - http://watch.bnn.ca/#clip697368

On a similar note, late last Friday afternoon Byron Capital’s Health Care Analyst, Doug Loe also named Neptune as a Top Pick on BNN. Mr. Loe reiterated his $6 buy target on the stock and sites Neptune’s record revenues over the last three quarters,  he also discusses the current Acasti clinical studies.

View Doug Loe’s spot on BNN, click here - http://watch.bnn.ca/#clip695781  (Neptune is mentioned at the 5:25 mark)